tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Angioedema D000799 6 associated lipids
Anus Diseases D001004 3 associated lipids
Apraxias D001072 1 associated lipids
Arm Injuries D001134 1 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gaweco AS et al. Distinct intragraft cytokine gene expression patterns during acute hepatic rejection under cyclosporine versus FK 506 primary immunosuppression. 1994 Transplant. Proc. pmid:7527948
Burke GW et al. The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. 1995 Transplant. Proc. pmid:8539874
Ueki M et al. Peritoneal-omental pouch as a site for islet allotransplantation. 1994 Transplant. Proc. pmid:7513462
Valdivia LA et al. Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. 1993 Transplant. Proc. pmid:7679816
Yasunami Y et al. Acceptance of donor-specific islet allografts in rat by intraportal preimmunization with islets and FK 506. 1994 Transplant. Proc. pmid:7513467
Alejandro R et al. Combined liver-islet allotransplantation in man under FK 506. 1991 Transplant. Proc. pmid:1703712
Zeevi A et al. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689884
Pascual J and Ortuño J Simple tacrolimus-based immunosuppressive regimens following renal transplantation: a large multicenter comparison between double and triple therapy. 2002 Transplant. Proc. pmid:11959198
Gamboa O et al. Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation. 2011 Transplant. Proc. pmid:22099798
Fougeray S et al. Increased body mass index after kidney transplantation in activating transcription factor 6 single polymorphism gene carriers. 2011 Transplant. Proc. pmid:22099811
Grewal HP et al. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. 1998 Transplant. Proc. pmid:9636558
Fernández A et al. Complete switch to everolimus in long-term kidney transplants: evolution of the renal function. 2009 Jul-Aug Transplant. Proc. pmid:19715915
Marcén R et al. Evolution of rejection rates and kidney graft survival: a historical analysis. 2009 Jul-Aug Transplant. Proc. pmid:19715918
Chueh SC et al. Drug fever caused by mycophenolate mofetil in a renal transplant recipient--a case report. 2000 Transplant. Proc. pmid:11120003
Vathsala A et al. Inhibition of apoptosis in anti-CD3-treated peripheral blood lymphocytes by immunosuppressive drugs. 2000 Transplant. Proc. pmid:11120034
Shibata T et al. Does FK 506 accelerate the development of coronary artery disease in the transplanted heart as well as the native heart? 1993 Transplant. Proc. pmid:7680147
Todo S et al. Intestinal transplantation in humans under FK 506. 1993 Transplant. Proc. pmid:7680148
Cofan F et al. Effect of calcineurin inhibitors on low-density lipoprotein oxidation. 2005 Transplant. Proc. pmid:16386540
Wu YM et al. Interaction between FK 506 and cyclosporine in dogs. 1991 Transplant. Proc. pmid:1721281
Habucky K et al. The pharmacodynamics of pentobarbital following FK 506 therapy. 1991 Transplant. Proc. pmid:1721282
Horimoto H et al. Hepatocyte xenotransplantation for Nagase's analbuminemic rats: the effect of FK506. 1996 Transplant. Proc. pmid:8623421
Sung RS et al. Survival of human islet xenografts irradiated with ultraviolet B in diabetic rats. 1996 Transplant. Proc. pmid:8623427
Díaz-Molina B et al. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. 2012 Transplant. Proc. pmid:23146479
San Segundo D et al. Study of B-cell subpopulations in lung transplant recipients with posttransplant infection. 2012 Transplant. Proc. pmid:23146491
Tekgündüz E et al. Electrolyte free water clearance could be an early sign of renal dysfunction in renal transplant patients. 2009 Transplant. Proc. pmid:19917375
Lipson DA et al. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. 1998 Transplant. Proc. pmid:9636612
Zawiasa A et al. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus. 2009 Jan-Feb Transplant. Proc. pmid:19249511
Hohage H et al. Cyclosporine and tacrolimus: influence on cardiovascular risk factors. 2005 Transplant. Proc. pmid:15848615
Yasutomi M et al. Mechanism of antibody production in hamster-to-rat concordant xenotransplantation: establishment of a simple model using intravenous injection of concordant splenocytes. 1994 Transplant. Proc. pmid:7518110
Schuller S et al. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation. 2005 Transplant. Proc. pmid:15848653
Mueller AR et al. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A. 1995 Transplant. Proc. pmid:7533359
Kita J et al. Effects of tacrolimus on small and large bowel anastomoses in the rat. 1999 Transplant. Proc. pmid:10578292
Woo J et al. Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. 1991 Transplant. Proc. pmid:1721313
Azuma T et al. Study of graft-infiltrating cells in the rat small bowel allograft using low-dose FK 506. 1999 Transplant. Proc. pmid:10578293
Telkes G et al. Kidney transplantation in hereditary coproporphyria using tacrolimus and mycophenolate mofetil: a case report. 2013 Transplant. Proc. pmid:24315002
Ebbs A et al. Tacrolimus treats ongoing allograft rejection by inhibiting interleukin-10 mediated functional cytotoxic cell infiltration. 2002 Transplant. Proc. pmid:12176404
Savikko J et al. Tacrolimus inhibits platelet-derived growth factor ligand and receptor induction as well as rejection changes in rat renal allografts during long-term follow-up. 2002 Transplant. Proc. pmid:12176405
Ã…berg F et al. Asymptomatic De Novo Inflammatory Bowel Disease Late After Liver Transplantation for Primary Sclerosing Cholangitis: A Case Report. 2015 Transplant. Proc. pmid:26680092
Heilman RL et al. Steroid avoidance immunosuppression in low-risk kidney transplant recipients. 2005 Transplant. Proc. pmid:15919466
Akita K and Mandel TE Effect of FK 506 and anti-CD4 monoclonal antibody treatment on xenografts of organ-cultured fetal pig pancreas and host lymphoid populations. 1993 Transplant. Proc. pmid:7692650
Tanabe M et al. Therapeutic synergism between low-dose FK 506 and antimetabolites in rat allogeneic heart transplantation. 1995 Transplant. Proc. pmid:7533411
Masri MA Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in BALB/c mice with fitted skin grafts. 1995 Transplant. Proc. pmid:7533412
Mieles LA et al. Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. 1991 Transplant. Proc. pmid:1721344
Nakazato P et al. Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. 1991 Transplant. Proc. pmid:1721345
Bortman GV et al. South American Heart Transplantation Registry of patients receiving everolimus in their immunosuppressive regimens. 2010 Jan-Feb Transplant. Proc. pmid:20172342
Parada MT et al. Everolimus in lung transplantation in Chile. 2010 Jan-Feb Transplant. Proc. pmid:20172343
Reis A et al. Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation. 1998 Transplant. Proc. pmid:9865380
Malaise J et al. Tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: the EURO-SPK 3-year results. 2005 Jul-Aug Transplant. Proc. pmid:16182828
Naraghi RM et al. Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123013
Meçule A et al. Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once-daily regimen. 2011 Transplant. Proc. pmid:21620040
Calia R et al. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation. 2011 Transplant. Proc. pmid:21620041
Velio P et al. Rejection and survival after total orthotopic liver-small bowel allotransplantation in pigs immunosuppressed with FK 506. 1996 Transplant. Proc. pmid:8907936
Matsuura T et al. Organ-specific tolerance induced by intrathymic injection of donor bone marrow cells and FK 506 or antilymphocyte serum in rat heart transplantation. 1994 Transplant. Proc. pmid:7520616
Watanabe T et al. Effects of the endothelin-1 receptor antagonist TAK-044 on pulmonary injury in discordant xenotransplantation. 2000 Transplant. Proc. pmid:10936270
Boots JM et al. Pretransplant pharmacokinetics: does it predict the dose of tacrolimus after renal transplantation? 2002 Transplant. Proc. pmid:12493409
Ueda D et al. Influence of FK 506 on renal blood flow. 1991 Transplant. Proc. pmid:1721377
Peraira JR et al. High incidence of severe infections in heart transplant recipients receiving tacrolimus. 2003 Transplant. Proc. pmid:12962875
Pisitkun T et al. The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. 2002 Transplant. Proc. pmid:12493410
Thomson AW et al. The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. 1991 Transplant. Proc. pmid:1703361
Perico N et al. FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. 1991 Transplant. Proc. pmid:1721378
Zegarska J et al. Evaluation of the Relationship Between Concentrations of Tacrolimus Metabolites, 13-O-Demethyl Tacrolimus and 15-O-Demethyl Tacrolimus, and Clinical and Biochemical Parameters in Kidney Transplant Recipients. 2018 Transplant. Proc. pmid:30177142
Mieles L et al. Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. 1991 Transplant. Proc. pmid:1703362
Okamoto M et al. Tacrolimus-based immunosuppression in renal transplantation: 78 experiences in a single Japanese center. 2002 Transplant. Proc. pmid:12176527
Tanabe K et al. Improved outcome of minor-mismatched living renal allografts under tacrolimus immunosuppression. 2002 Transplant. Proc. pmid:12176528
Rastellini C et al. Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. 1999 Feb-Mar Transplant. Proc. pmid:10083278
Tsuchiya T et al. Effect of conversion from twice-daily to once-daily tacrolimus on glucose intolerance in stable kidney transplant recipients. 2012 Transplant. Proc. pmid:22310593
Hatakeyama S et al. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients. 2012 Transplant. Proc. pmid:22310594
Millis JM et al. Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy. 1997 Feb-Mar Transplant. Proc. pmid:9123421
Mollison KW et al. Discovery of FK 506 analogues that are nontoxic to mouse pancreatic beta cells in vitro but show diabetogenic potential when administered to the rat. 1996 Transplant. Proc. pmid:8962236
Pelekanou V et al. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. 1991 Transplant. Proc. pmid:1721408
Taki J et al. DNA analysis of peripheral blood mononuclear cells for early detection of hepatic graft rejection. 1992 Transplant. Proc. pmid:1379760
Nagashima N et al. Immunocompetence assay for net effect of combined immunosuppression. 2001 Transplant. Proc. pmid:11377556
Baran DA et al. Tacrolimus and cardiac transplantation: a comparison of monotherapy and steroid-dependent patients. 2002 Transplant. Proc. pmid:12176599
Chan MC et al. Conversion of cyclosporine to tacrolimus for refractory or persistent myocardial rejection. 2002 Transplant. Proc. pmid:12176601
Calconi G and Vianello A One-year follow-up of a large European trial comparing dual versus triple tacrolimus-based immunosuppressive regimens following renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267173
Pretagostini R et al. Conversion from cyclosporin to tacrolimus in chronic allograft nephropathy. 2001 Feb-Mar Transplant. Proc. pmid:11267174
Lang M et al. Combined liver-kidney transplantation: long-term follow-up in 18 patients. 1998 Transplant. Proc. pmid:9723313
Behr TM et al. Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A. 1998 Transplant. Proc. pmid:9723333
Ji SM et al. Rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil for C4d-positive acute humoral renal allograft rejection. 2006 Transplant. Proc. pmid:17175303
Ersoy A et al. Diabetic ketoacidosis following development of de novo diabetes in renal transplant recipient associated with tacrolimus. 2004 Transplant. Proc. pmid:15251345
López-Vilella R et al. Incidence of development of obesity after heart transplantation according to the calcineurin inhibitor. Transplant. Proc. pmid:25645789
Jiang H et al. Prolonged cardiac allograft survival in sensitized rats by low-dose FK 506 in combination with splenectomy. 1991 Transplant. Proc. pmid:1721439
Sato K et al. Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. 1991 Transplant. Proc. pmid:1721440
Makowka L et al. The effect of FK-506 on hyperacute rejection in presensitized rats. 1987 Transplant. Proc. pmid:2445082
Katayama Y et al. Immunosuppressive effects of FK 506 in rat lung transplantation. 1991 Transplant. Proc. pmid:1721441
Odocha O et al. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689268
Ochiai T et al. Effects of FK-506 on xenotransplantation of the heart and skin in a mouse-rat combination. 1987 Transplant. Proc. pmid:2445083
Odocha O et al. Serum cholesterol levels in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689269
Nalesnik MA et al. Toxicology of FK-506 in the Lewis rat. 1987 Transplant. Proc. pmid:2445084
Martín-Fernández M et al. Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. 2017 Transplant. Proc. pmid:29149986
Langrehr JM et al. IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267360
González-Pinto I et al. Usefulness of the switch to tacrolimus in liver transplantation. 1999 Transplant. Proc. pmid:10500653
Mita A et al. Optimal initial dose of orally administered once-daily extended-release tacrolimus following intravenous tacrolimus therapy after liver transplantation. 2014 Transplant. Proc. pmid:24767351
Haba T et al. Pathological and immunohistochemical examination in the rat treated with FK 506. 1991 Transplant. Proc. pmid:1714649
Morris-Stiff G et al. Preoperative induction with tacrolimus does not have a detrimental effect on primary graft function in adult cadaveric renal transplantation. 1998 Transplant. Proc. pmid:9636499
Eghtesad B et al. Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics. 1998 Transplant. Proc. pmid:9636500
Scholler G et al. Comparison of cyclosporine A and FK506 with regard to complaints and psychosocial characteristics before and after liver transplantation. 1997 Transplant. Proc. pmid:9270822
Pichlmayr R et al. Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study. 1997 Transplant. Proc. pmid:9270825
Pillet A et al. Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia. 2006 Transplant. Proc. pmid:16980083
Fisher A et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. 1994 Transplant. Proc. pmid:7527947